Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Recovery (May) | 2017

View Archived Issues

Take The CME Post-Test for Recovery, CATR, May 2017

May 1, 2017

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More

Eight Strategies to Help Patients Maintain Recovery

May 1, 2017

Matthew Goldenberg, DO

How can you help increase the odds that Robert, or any of your patients, will succeed in recovery? Here are eight key strategies that support long-term recovery. Read More

Recognizing and Reversing Relapse

May 1, 2017

Michael Weaver, MD

Addiction treatment often begins with high hopes and apparent success, but it’s important to remember that addiction is a disease with a relapse rate of 40%–60%. Be realistic: Expect that patients will go through cycles of relapse and recovery. Learn the warning signs for relapse, the measures you can take to prevent it, and what to do after it has occurred. Read More

Treatment vs. Recovery

May 1, 2017

Michael Pond, MSW, RN

For many people, the word “recovery” means being in AA or another 12-step program where the goal is to stay abstinent. It’s a culture of mutual support where people help and assist each other toward the goal of sobriety. Read More

Can a One-Week Naltrexone Detox Reduce Outpatient Opioid Relapse Rates?

May 1, 2017

Kirsten Pickard, BA

Naltrexone is an opioid blocker that is FDA-approved for the treatment of alcoholism. However, it is also effective off-label for treating opioid use disorder. The medication comes in two forms: an oral pill (brand name ReVia) and an injectable version (XR naltrexone, or Vivitrol). XR naltrexone is composed of 380 mg of naltrexone, given as an intramuscular injection once a month. During that month, patients who try to use opioids will feel little if any high. This works well to prevent relapse if patients keep getting the shot. Read More

Is Topiramate a Silver Bullet for Those Dually Dependent on Alcohol and Nicotine?

May 1, 2017

Kirsten Pickard, BA

People with alcohol use disorder are often smokers, and it can be very hard for patients to reduce their drinking and smoking simultaneously. In this study, the researchers hypothesized that topiramate, which has shown promise as an off-label treatment for nicotine and alcohol use independently, might work as a “silver bullet” for both problems. Read More